Leukemia, Myelomonocytic, Chronic
Information
- Disease name
- Leukemia, Myelomonocytic, Chronic
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04266301 | Active, not recruiting | Phase 3 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | April 14, 2013 | September 17, 2024 |
| NCT03268954 | Active, not recruiting | Phase 3 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | November 28, 2017 | June 30, 2024 |
| NCT05883956 | Active, not recruiting | Phase 3 | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia | December 20, 2023 | May 2025 |
| NCT00761722 | Completed | Phase 1 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | August 12, 2008 | April 7, 2016 |
| NCT01464047 | Completed | Korean Post-marketing Surveillance for Sprycel® | October 2011 | August 2015 | |
| NCT01519011 | Completed | Phase 1 | Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | February 7, 2012 | May 12, 2015 |
| NCT02085798 | Completed | Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment) | December 17, 2012 | December 14, 2018 | |
| NCT02201329 | Completed | Phase 1 | Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | August 2014 | September 2015 |
| NCT02472691 | Completed | Phase 2 | Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT | May 2015 | April 23, 2020 |
| NCT02610777 | Completed | Phase 2 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | April 14, 2016 | July 23, 2021 |
| NCT00025662 | Completed | Phase 2 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | May 2001 | February 2008 |
| NCT00255346 | Completed | Phase 2 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | November 15, 2005 | March 3, 2017 |
| NCT00744536 | Completed | Phase 2 | Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS | January 2008 | December 2012 |
| NCT02807272 | Completed | Phase 2 | Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia | October 2016 | December 14, 2020 |
| NCT02891551 | Completed | An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands | May 1, 2012 | December 30, 2018 | |
| NCT02907359 | Completed | Phase 3 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | January 13, 2017 | November 30, 2020 |
| NCT03814005 | Completed | Phase 1 | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | July 10, 2019 | April 19, 2022 |
| NCT05218902 | Completed | A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | February 25, 2022 | March 20, 2023 | |
| NCT05201066 | Recruiting | Phase 2 | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | February 13, 2023 | February 14, 2028 |
| NCT02760238 | Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry | April 2016 | October 2025 | |
| NCT03175978 | Terminated | Phase 1/Phase 2 | IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome | February 21, 2018 | September 30, 2021 |
| NCT00109538 | Terminated | Phase 3 | Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) | May 2005 | August 2008 |
| NCT01957644 | Terminated | Phase 1 | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | November 6, 2013 | December 16, 2016 |
| NCT02841540 | Terminated | Phase 1 | A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes | October 6, 2016 | February 13, 2024 |
| NCT00510289 | Terminated | Phase 2 | Sorafenib in Myelodysplastic Syndrome | July 2006 | July 2011 |
| NCT03040401 | Unknown status | Phase 1/Phase 2 | A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) | February 15, 2017 | December 15, 2019 |
| NCT04264806 | Withdrawn | Phase 2 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | May 6, 2021 | January 28, 2025 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D015477